Table 2. Circumstances when arsenic... | American Society of Hematology

Table 2.

Circumstances when arsenic trioxide could be used as initial therapy in acute promyelocytic leukemia (APL).

In induction and consolidation with minimal, if any, chemotherapy if unable to receive or tolerate chemotherapy with all-trans retinoic acid (ATRA)
- Cardiac failure
- Therapy-related APL (prior anthracyclines)
- Elderly +/− poor performance status
- Refusal of chemotherapy
In induction and consolidation with minimal, if any, chemotherapy in very low risk and perhaps low-risk patients.
In consolidation following conventional induction with ATRA and anthracycline-based chemotherapy, esp. high-risk patients.
Not based on leukemia cell biology [additional cytogenetic abnormalities, FLT3, CD56, promyelocytic (PML) isoform].